Literature DB >> 25950215

Economic evaluation of hybrid capture human papillomavirus testing in women with low-grade papanicolaou smear abnormalities.

A Lytwyn1, A Gafni, J W Sellors, R Goeree, J Randazzo, J B Mahony, D Daya.   

Abstract

OBJECTIVES: Our aim was to determine the cost-effectiveness of three strategies for detecting cervical intraepithelial neoplasia 2 and 3 after a determination of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion on screening Papanicolaou (Pap) smear.
METHODS: Single repeat Pap smear. Hybrid Capture testing for human papillomavirus, and immediate colposcopy were compared. A theoretical decision analysis model was constructed with 10,000 women in each group. Costs and outcomes are those of diagnosis and treatment of cervical intraepithelial neoplasia (CIN) 2 or 3. Outcome probabilities and utilization data were obtained from a literature review and expert opinion.
RESULTS: Repeat smear detected 1,125 cases, Hybrid Capture, 1,350 cases, and colposcopy, 1,482 cases of CIN2 or CIN3, costing $1,490,000, $1,980,000, and $2,420,000, respectively. Incremental cost per high-grade dysplasia was $2,178 for Hybrid Capture and $3,333 for colposcopy. Sensitivity analyses that test management efficiencies are reported.
CONCLUSIONS: More effective strategies are more costly. However, if costs saved by preventing invasive cancers are included, all three strategies may be cost-saving.

Entities:  

Year:  1998        PMID: 25950215     DOI: 10.1097/00128360-199810000-00006

Source DB:  PubMed          Journal:  J Low Genit Tract Dis        ISSN: 1089-2591            Impact factor:   1.925


  2 in total

1.  Comparison of human papillomavirus DNA testing and repeat Papanicolaou test in women with low-grade cervical cytologic abnormalities: a randomized trial. HPV Effectiveness in Lowgrade Paps (HELP) Study No. 1 Group.

Authors:  A Lytwyn; J W Sellors; J B Mahony; D Daya; W Chapman; N Ellis; P Roth; A T Lorincz; A Gafni
Journal:  CMAJ       Date:  2000-09-19       Impact factor: 8.262

2.  Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection.

Authors:  E L Franco; E Duarte-Franco; A Ferenczy
Journal:  CMAJ       Date:  2001-04-03       Impact factor: 8.262

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.